You are here: Industry Insights > teva

News List

Teva drops development of laquinimod pharmatimes
September 14, 2018
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech.
Teva attracts attention from pharma, private equity for $500M sale of Medis fiercepharma
September 14, 2018
Teva has been working to pay down tens of billions of dollars of debt since it purchased Allergan’s generics suite for more than $40 billion. Now, the company's Medis unit has attracted attention from industry players and private equity firms, according t
Active Biotech regains rights of laquinimod from Teva biospectrum
September 10, 2018
Laquinimod, an orally administered small molecule has primarily been developed as a potential treatment of neurodegenerative diseases such as multiple sclerosis (MS) and Huntington's disease (HD).
Teva wins FDA nod for its generic of Mylan's EpiPen after 2-year delay fiercepharma
August 20, 2018
After a delay of more than two years, Teva has won approval of its generic version of Mylan’s highly successful EpiPens. The approval comes at an opportune time given that manufacturing issues have made supplies of Mylan’s epinephrine injectors spotty, le
Teva scoffs at whistleblowers' evidence in bid to dismiss kickbacks case fiercepharma
August 17, 2018
After whistleblowers reached their "put up or shut up" moment for producing solid evidence of Copaxone and Azilect kickbacks—and didn't, Teva says—the generics giant has urged a judge to toss the allegations.
Regeneron, Teva’s pain drug clears phase 3 efficacy bar fiercebiotech
August 17, 2018
A phase 3 osteoarthritis trial of Teva and Regeneron’s fasinumab has met its co-primary endpoints. The anti-NGF antibody cleared the efficacy bar but triggered the expected safety alarms......
Teva confident in September approval for migraine drug despite latest Celltrion plant citation fiercepharma
August 09, 2018
The FDA has reinspected a Celltrion plant in South Korea after issuing it a warning letter earlier in the year. Although the July visit resulted in another FDA Form 483, Teva officials are confident the findings will not delay the expected approval next m
Teva Announces Updated Indication, Vial Presentation for Granix americanpharmaceuticalreview
August 07, 2018
Teva announced the U.S. Food and Drug Administration (FDA) has approved Granix (tbo-filgrastim) Injection for a new vial presentation and indication in pediatric patients one month and older.
Teva raises earnings estimates despite continuing troubles pharmatimes
August 03, 2018
Teva has raised its annual earnings guidance as it reported a smaller-than-expected drop in profits for Q2, a good sign for the company's ongoing restructuring programme.
Teva's picked an address in Parsippany, New Jersey, and the dirt's about to fly fiercepharma
July 30, 2018
Teva now knows where it's headed in New Jersey, but it’s still got plenty of work to do before it can move into its new U.S. headquarters.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page